<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/mostaccessed/journal?journal=bmcwomenshealth&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Women&apos;s Health - Most accessed articles</title>
        <link>http://www.biomedcentral.com/bmcwomenshealth/</link>
        <description>The most accessed research articles published by BMC Women&apos;s Health</description>
        <dc:date>2009-11-19T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/6/6" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/9/21" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/9/27" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/9/32" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/9/31" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/9/28" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/9/24" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/9/29" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/9/22" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/9/30" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/6/6">
        <title>Female genital mutilation of a karyotypic male presenting as a female with delayed puberty</title>
        <description>Background:
Female genital mutilation (FGM) is commonly practiced mainly in a belt reaching from East to West Africa north of the equator. The practice is known across socio-economic classes and among different ethnic, religious, and cultural groups. Few studies have been appropriately designed to measure the health effects of FGM. However, the outcome of FGM on intersex individuals has never been discussed before.Case presentationThe patient first presented as a female with delayed puberty. Hormonal analysis revealed a normal serum prolactin level of 215 Mu/L, a low FSH of 0.5 Mu/L, and a low LH of 1.1 Mu/L. Type IV FGM (Pharaonic circumcision) had been performed during childhood. Chromosomal analysis showed a 46, XY karyotype and ultrasonography verified a soft tissue structure in the position of the prostate.
Conclusion:
FGM pose a threat to the diagnosis and management of children with abnormal genital development in the Sudan and similar societies.</description>
        <link>http://www.biomedcentral.com/1472-6874/6/6</link>
                <dc:creator>Mona Ellaithi</dc:creator>
                <dc:creator>Therese Nilsson</dc:creator>
                <dc:creator>David Gisselsson</dc:creator>
                <dc:creator>Atif Elagib</dc:creator>
                <dc:creator>Hamid Eltigani</dc:creator>
                <dc:creator>Imad Fadl- Elmula</dc:creator>
                <dc:source>BMC Women&apos;s Health 2006, 6:6</dc:source>
        <dc:date>2006-03-29T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-6-6</dc:identifier>
        <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2006-03-29T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/9/21">
        <title>Pattern recognition in menstrual bleeding diaries 
by statistical cluster analysis</title>
        <description>Background:
The aim of this paper is to empirically identify a treatment-independent statistical method to describe clinically relevant bleeding patterns by using bleeding diaries of clinical studies on various sex hormone containing drugs.
Methods:
We used the four cluster analysis methods single, average and complete linkage as well as the method of Ward for the pattern recognition in menstrual bleeding diaries.The optimal number of clusters was determined using the semi-partial R2, the cubic cluster criterion, the pseudo-F- and the pseudo-t2-statistic. Finally, the interpretability of the results from a gynecological point of view was assessed.
Results:
The method of Ward yielded distinct clusters of the bleeding diaries. The other methods successively chained the observations into one cluster. The optimal number of distinctive bleeding patterns was six. We found two desirable and four undesirable bleeding patterns. Cyclic and non cyclic bleeding patterns were well separated.
Conclusion:
Using this cluster analysis with the method of Ward medications and devices having an impact on bleeding can be easily compared and categorized.</description>
        <link>http://www.biomedcentral.com/1472-6874/9/21</link>
                <dc:creator>Christoph Gerlinger</dc:creator>
                <dc:creator>Jens Wessel</dc:creator>
                <dc:creator>Gerd Kallischnigg</dc:creator>
                <dc:creator>Jan Endrikat</dc:creator>
                <dc:source>BMC Women&apos;s Health 2009, 9:21</dc:source>
        <dc:date>2009-07-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-9-21</dc:identifier>
        <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>21</prism:startingPage>
        <prism:publicationDate>2009-07-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/9/27">
        <title>Factors affecting awareness of emergency contraception 
among college students in Kathmandu, Nepal</title>
        <description>Background:
In Nepal, Emergency Contraception (EC) could play a critical role in reducing unintended pregnancies, but very few people aware about it. This paper aims to investigate the level of awareness and factors influencing awareness of EC among college students.
Methods:
A cross-sectional study was carried out in April-May 2006. Structured self-administered questionnaires were administered to 1,137 college students (573 males and 564 females) in Kathmandu valley. The association between awareness of EC and the explanatory variables were first assessed in bivariate analysis using the Chi-square test. The associations were further explored using a multivariate logistic analysis.
Results:
Only about two-thirds of college students (68%) had ever heard about EC. Bivariate analysis shows that males were more aware (72%) of EC than were females (64%). Similarly, the awareness level was significantly higher among younger, unmarried youth who were from outside Kathmandu Valley, who lived with friends, and who had received reproductive health (RH) education in school/college. The study also found that students&apos; sex, permanent place of residence (district), and RH education are significant predictors of awareness of EC. Males are 1.5 times more likely to be aware of EC compared to females. Furthermore, students who lived in Kathmandu Valley were 41% less likely to be aware of EC than were students from outside Kathmandu Valley. On the other hand, those students who received RH education in school/college were almost nine times more likely to be aware of EC compared to those who did not receive such education.
Conclusion:
Awareness of the EC is low among college students in Nepal. Health education initiatives should target students as they are more likely to be sexually active. There is a need to further educate students about EC which can help to reduce unintended pregnancies, many of which result in unsafe abortion and take a large toll on women&apos;s health.</description>
        <link>http://www.biomedcentral.com/1472-6874/9/27</link>
                <dc:creator>Ramesh Adhikari</dc:creator>
                <dc:source>BMC Women&apos;s Health 2009, 9:27</dc:source>
        <dc:date>2009-09-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-9-27</dc:identifier>
        <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>27</prism:startingPage>
        <prism:publicationDate>2009-09-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/9/32">
        <title>Physical activity patterns during pregnancy through postpartum</title>
        <description>Background:
Realizing the importance of regular physical activity, particularly in the prevention of chronic diseases and unhealthy weight gain, it is important to study how physical activity changes during and after pregnancy using prospective study designs. The aim of this study was to describe the mode, duration, intensity, and changes in physical activity during pregnancy through one year postpartum among a cohort of women.
Methods:
This study was part of the third Pregnancy, Infection and Nutrition Postpartum Study at the University of North Carolina Hospitals. A cohort of 471 women was followed at 17-22 and 27-30 weeks&apos; gestation and at 3 and 12 months postpartum. The participants reported the mode, frequency, duration, and intensity of all physical activities that increased their breathing and heart rate in the past week.
Results:
Overall physical activity for the cohort decreased from 17-22 weeks to 27-30 weeks of gestation, but rebounded up at 3 months postpartum and remained stable at 12 months postpartum. The mean MET h/wk values for each time point were 24.7 (standard deviation, SD 26.8), 19.1 (SD 18.9), 25.7 (SD 29.3), and 26.7 (SD 31.5). In postpartum, women reported more care-giving and recreational activity and less indoor household activity, as compared to their activity level during pregnancy.
Conclusion:
For health benefits and weight management, health care professionals are encouraged to provide pregnant and postpartum women with information on recommendations of physical activity, particularly regarding the minimum duration and intensity level.</description>
        <link>http://www.biomedcentral.com/1472-6874/9/32</link>
                <dc:creator>Katja Borodulin</dc:creator>
                <dc:creator>Kelly Evenson</dc:creator>
                <dc:creator>Amy Herring</dc:creator>
                <dc:source>BMC Women&apos;s Health 2009, 9:32</dc:source>
        <dc:date>2009-11-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-9-32</dc:identifier>
        <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>32</prism:startingPage>
        <prism:publicationDate>2009-11-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/9/31">
        <title>The effect of past use of oral contraceptive on bone mineral density, bone biochemical markers and muscle strength in healthy pre and post menopausal women</title>
        <description>Background:
during adulthood, most studies have reported that oral contraceptive (OC) pills had neutral, or possibly beneficial effect on bone health. We proposed this study of pre and post menopausal women assessing BMD, bone biochemical markers and physical performance among OC past users and comparable women who have never use Ocs.
Methods:
A cross-sectional study comparing the bone density, bone biochemical markers (osteocalcin, CTX) and three measures to assess physical performance: timed get-up-and-go test &quot;TGUG&quot;, five-times-sit-to-stand test &quot;5 TSTS&quot; and 8-feet speed walk &quot;8 FSW&quot; of users and never users OC. We were recruited 210 women who used OC for at least 2 years with that of 200 nonusers was carried out in pre and postmenopausal women (24-86 years).
Results:
when analysing the whole population, BMD and biochemical markers values were similar for Ocs past users and control subjects. However when analysing the subgroup of premenopausal women, there was a statistically significant difference between users and never-users in osteocalcin (15,5 &#177; 7 ng/ml vs 21,6 &#177; 9 ng/ml; p = 0,003) and CTX (0,30 &#177; 0,1 ng/ml vs 0,41 &#177; 0,2 ng/ml; p = 0,025). This difference persisted after adjustment for age, BMI, age at menarche and number of pregnancies. In contrast, in post menopausal women, there was no difference in bone biochemical markers between OC users and the control. On the other hand OC past users had a significant greater performance than did the never users group. And when analysing the physical performance tests by quartile OC duration we found a significant negative association between the three tests and the use of OC more than 10 years.
Conclusion:
the funding show no evidence of a significant difference in BMD between Ocs users and never user control groups, a decrease in bone turn over in OC pre menopausal users and a greater physical performances in patients who used OC up than 10 years.</description>
        <link>http://www.biomedcentral.com/1472-6874/9/31</link>
                <dc:creator>Fadoua Allali</dc:creator>
                <dc:creator>Laila El Mansouri</dc:creator>
                <dc:creator>Fatima zohra Abourazzak</dc:creator>
                <dc:creator>Linda Ichchou</dc:creator>
                <dc:creator>Hamza Khazzani</dc:creator>
                <dc:creator>Loubna Bennani</dc:creator>
                <dc:creator>Radouan Abouqal</dc:creator>
                <dc:creator>Najia Hajjaj-Hassouni</dc:creator>
                <dc:source>BMC Women&apos;s Health 2009, 9:31</dc:source>
        <dc:date>2009-11-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-9-31</dc:identifier>
        <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>31</prism:startingPage>
        <prism:publicationDate>2009-11-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/9/28">
        <title>Complications associated with transobturator sling procedures: analysis of 233 consecutive cases with a 27 months follow-up</title>
        <description>BackroundThe transobturator tape procedure (TOT) is an effective surgical treatment of female stress urinary incontinence. However data concerning safety are rare, follow-up is often less than two years, and complications are probably underreported. The aim of this study was to describe early and late complications associated with TOT procedures and identify risk factors for erosions.
Methods:
It was a 27 months follow-up of a cohort of 233 women who underwent TOT with three different types of slings (Aris&#174;, Obtape&#174;, TVT-O&#174;). Follow-up information was available for 225 (96.6%) women.
Results:
There were few per operative complications. Forty-eight women (21.3%) reported late complications including de novo or worsening of preexisting urgencies (10.2%), perineal pain (2.2%), de novo dyspareunia (9%), and vaginal erosion (7.6%). The risk of erosion significantly differed between the three types of slings and was 4%, 17% and 0% for Aris&#174;, Obtape&#174; and TVT-O&#174; respectively (P = 0.001). The overall proportion of women satisfied by the procedure was 72.1%. The percentage of women satisfied was significantly lower in women who experienced erosion (29.4%) compared to women who did not (78.4%) (RR 0.14, 95% CI 0.05-0.38, P &lt; 0.001).
Conclusion:
Late post operative complications are relatively frequent after TOT and can impair patient&apos;s satisfaction. Women should be informed of these potential complications preoperatively and require careful follow-up after the procedure. Choice of the safest sling material is crucial as it is a risk factor for erosion.</description>
        <link>http://www.biomedcentral.com/1472-6874/9/28</link>
                <dc:creator>Isabelle Kaelin-Gambirasio</dc:creator>
                <dc:creator>Sandrine Jacob</dc:creator>
                <dc:creator>Michel Boulvain</dc:creator>
                <dc:creator>Jean-Bernard Dubuisson</dc:creator>
                <dc:creator>Patrick Dallenbach</dc:creator>
                <dc:source>BMC Women&apos;s Health 2009, 9:28</dc:source>
        <dc:date>2009-09-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-9-28</dc:identifier>
        <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>28</prism:startingPage>
        <prism:publicationDate>2009-09-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/9/24">
        <title>Protocol for Physiotherapy OR Tvt Randomised Efficacy Trial (PORTRET): a multicenter randomised controlled trial to assess the cost-effectiveness of the tension free vaginal tape versus pelvic floor muscle training in women with symptomatic moderate to severe stress urinary incontinence.</title>
        <description>Background:
Stress urinary incontinence is a common condition affecting approximately 20% of adult women causing substantial individual (quality of life) and economic (119 million Euro/year spent on incontinence pads in the Netherlands) burden. Pelvic floor muscle training (PFMT) is regarded as first line treatment, but only 15-25% of women will be completely cured. Approximately 65% will report that their condition improved, but long term adherence to treatment is problematic. In addition, at longer term (2-15 years) follow-up 30-50% of patients will end up having surgery. From 1996 a minimal invasive surgical procedure, the Tension-free Vaginal Tape (TVT) has rapidly become the gold standard in surgical treatment of stress urinary incontinence. With TVT 65-95% of women are cured. However, approximately 3-6% of women will develop symptoms of an overactive bladder, resulting in reduced quality of life. Because of its efficacy the TVT appears to be preferable over PFMT but both treatments and their costs have not been compared head-to-head in a randomised clinical trial.Methods/DesignA multi-centre randomised controlled trial will be performed for women between 35 - 80 years old with moderate to severe, predominantly stress, urinary incontinence, who have not received specialised PFMT or previous anti-incontinence surgery. Women will be assigned to either PFMT by a specialised physiotherapist for a standard of 9-18 session in a period of 6 months, or TVT(O) surgery. The main endpoint of the study is the subjective improvement of urinary incontinence. As secondary outcome the objective cure will be assessed from history and clinical parameters. Subjective improvement in quality of life will be measured by generic (EQ-5D) and disease-specific (Urinary Distress Inventory and Incontinence Impact Questionnaire) quality of life instruments. The economical endpoint is short term (1 year) incremental cost-effectiveness in terms of costs per additional year free of urinary incontinence and costs per Quality Adjusted Life Years (QALY) gained. Finally, treatment strategy and patient characteristics will be combined in a prediction model, to allow for individual treatment decisions in future patients. Four hundred female patients will be recruited from over 30 hospitals in the NetherlandsTrial registrationNederlands trial register: NTR 1248</description>
        <link>http://www.biomedcentral.com/1472-6874/9/24</link>
                <dc:creator>Julien Labrie</dc:creator>
                <dc:creator>Yolanda van der Graaf</dc:creator>
                <dc:creator>Erik Buskens</dc:creator>
                <dc:creator>Stella Tiersma</dc:creator>
                <dc:creator>Huub van der Vaart</dc:creator>
                <dc:source>BMC Women&apos;s Health 2009, 9:24</dc:source>
        <dc:date>2009-09-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-9-24</dc:identifier>
        <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>24</prism:startingPage>
        <prism:publicationDate>2009-09-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/9/29">
        <title>Age at menarche and the menstrual pattern of secondary school adolescents in northwest Ethiopia</title>
        <description>Background:
Population studies on normal and dysfunctional characteristics of menstrual cycles are scarce in Ethiopia. In addition variability in menarcheal age and menstrual characteristics are common. Knowledge on this variability is necessary for patient education and to guide clinical evaluation.
Methods:
A cross sectional study was conducted in two small towns called Dabat and Kola Diba, northwest Ethiopia between April and May 2007. Systematic sampling method was used to select 622 school girls from two secondary schools. A pretested questionnaire prepared in Amharic was used to gather data. Selected girls cooperated in answering the questionnaire in their classrooms under the supervision of the research team. Only 612 of the adolescent females were included in the final analysis, of which 305 were from Koladiba High School and 307 from Dabat.
Results:
The age of the study subjects ranges between 14 and 19 with a mean (standard deviation) of 16.9 &#177; 1 years. About 92.2% had attained menarche by the time the survey was conducted. The probit analysis of the status quo data yielded a median (CI) age at menarche of 14.8 (13.9-15.3) years. The average age at menarche by recall method was 15.8 &#177; 1 years. The mean age at menarche was 0.3 years younger for urban females compared with rural ones (p &lt; 0.001). A cycle length between 21 and 35 days was observed in 70.3% of the girls. The mean duration of flow was 4 &#177; 1.3 days with a range of 2-7 days. The menstrual cycles were irregular in 42.8% of the subjects. The overall prevalence of dysmenorrhoea was 72% among these subjects. Premenstrual symptoms were present in 435 of the females (75.4%). The leading sources of menarcheal information to the adolescents were mothers (39.7%), followed by their friends (26.6%) and teachers (21.8%).
Conclusion:
In this study age of menarche was found to be delayed which is even higher than the findings indicated similar studies conducted in Ethiopia and other African countries. A significant number of students complain of abnormal menstrual cycle, dysmenorrhoea and premenstrual symptoms which call for appropriate counselling and management.</description>
        <link>http://www.biomedcentral.com/1472-6874/9/29</link>
                <dc:creator>Desalegn Zegeye</dc:creator>
                <dc:creator>Berihun Megabiaw</dc:creator>
                <dc:creator>Abay Mulu</dc:creator>
                <dc:source>BMC Women&apos;s Health 2009, 9:29</dc:source>
        <dc:date>2009-10-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-9-29</dc:identifier>
        <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>29</prism:startingPage>
        <prism:publicationDate>2009-10-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/9/22">
        <title>Protocol for the value of urodynamics prior to stress incontinence surgery (VUSIS) study: a multicenter randomized controlled trial to assess the cost effectiveness of urodynamics in women with symptoms of stress urinary incontinence in whom surgical treatment is considered.</title>
        <description>Background:
Stress urinary incontinence (SUI) is a common problem. In the Netherlands, yearly 64.000 new patients, of whom 96% are women, consult their general practitioner because of urinary incontinence. Approximately 7500 urodynamic evaluations and approximately 5000 operations for SUI are performed every year. In all major national and international guidelines from both gynaecological and urological scientific societies, it is advised to perform urodynamics prior to invasive treatment for SUI, but neither its effectiveness nor its cost-effectiveness has been assessed in a randomized setting.The Value of Urodynamics prior to Stress Incontinence Surgery (VUSIS) study evaluates the positive and negative effects with regard to outcome, as well as the costs of urodynamics, in women with symptoms of SUI in whom surgical treatment is considered.Methods/designA multicentre diagnostic cohort study will be performed with an embedded randomized controlled trial among women presenting with symptoms of (predominant) SUI.Urinary incontinence has to be demonstrated on clinical examination and/or voiding diary. Physiotherapy must have failed and surgical treatment needs to be under consideration.Patients will be excluded in case of previous incontinence surgery, in case of pelvic organ prolapse more than 1 centimeter beyond the hymen and/or in case of residual bladder volume of more than 150 milliliter on ultrasound or catheterisation.Patients with discordant findings between the diagnosis based on urodynamic investigation and the diagnosis based on their history, clinical examination and/or micturition diary will be randomized to operative therapy or individually tailored therapy based on all available information.Patients will be followed for two years after treatment by their attending urologist or gynaecologist, in combination with the completion of questionnaires.Six hundred female patients will be recruited for registration from approximately twenty-seven hospitals in the Netherlands. We aspect that one hundred and two women with discordant findings will be randomized.The primary outcome of this study is clinical improvement of incontinence as measured with the validated Dutch version of the Urinary Distress Inventory (UDI). Secondary outcomes of this study include costs, cure of incontinence as measured by voiding diary parameters, complications related to the intervention, re-interventions, and generic quality of life changes.Trial registrationClinical Trials NCT00814749.</description>
        <link>http://www.biomedcentral.com/1472-6874/9/22</link>
                <dc:creator>Sanne van Leijsen</dc:creator>
                <dc:creator>Kirsten Kluivers</dc:creator>
                <dc:creator>Ben Willem Mol</dc:creator>
                <dc:creator>Suzan Broekhuis</dc:creator>
                <dc:creator>Fred Milani</dc:creator>
                <dc:creator>C Huub Van der vaart</dc:creator>
                <dc:creator>Jan-Paul Roovers</dc:creator>
                <dc:creator>Marlies Bongers</dc:creator>
                <dc:creator>Jan den Boon</dc:creator>
                <dc:creator>Wilbert Spaans</dc:creator>
                <dc:creator>Jan Willem de Leeuw</dc:creator>
                <dc:creator>Viviane Dietz</dc:creator>
                <dc:creator>Jan Kleinjan</dc:creator>
                <dc:creator>Hans Brolmann</dc:creator>
                <dc:creator>Eveline Roos</dc:creator>
                <dc:creator>Judith Schaafstra</dc:creator>
                <dc:creator>John Heesakker</dc:creator>
                <dc:creator>Mark Vierhout</dc:creator>
                <dc:source>BMC Women&apos;s Health 2009, 9:22</dc:source>
        <dc:date>2009-07-21T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-9-22</dc:identifier>
        <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>22</prism:startingPage>
        <prism:publicationDate>2009-07-21T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/9/30">
        <title>Suboptimal management of severe menopausal symptoms by Nigerian Gynaecologists: a call for mandatory continuing medical education for physicians.</title>
        <description>Background:
Effective management of menopause is an important way to improve the quality of life of the increasing number of older women. The study sought to find out if Nigerian Gynaecologists offer effective treatment for severe menopausal symptoms.
Methods:
126 Nigerian Gynaecologists representing the six health zones of Nigeria were interviewed to determine the menopausal symptoms they had ever encountered in their practices, frequency of the symptoms, treatments ever offered for severe symptoms including their attitude to, and practice of hormone replacement therapy.
Results:
A Nigerian Gynaecologist encountered an average of one patient with menopausal symptoms every three months (range: 0-3 patients per month). The commoner symptoms they encountered were hot flushes (88%), insomnia (75.4%), depression (58.0%), irritability (56.3%), night sweats (55.6%) and muscle pains (54.8%) while urinary symptoms (16.7%) and fracture (1.6%) were less common. Treatments ever offered for severe symptoms were reassurance (90.5%), anxiolytics (68.3%), analgesics (14.3), HRT (7.9%), Vitamins (4%), Beta-blockers (3.2%) and Danazol (2.4%). These treatments were offered as a matter of institutional traditions rather than being based on any evidence of their efficacy.
Conclusion:
The result revealed that most Nigerian Gynaecologists prefer reassurance and anxiolytics for managing severe menopausal symptoms instead of evidence-based effective therapies. A policy of mandatory continuing medical education for Nigerian physicians is recommended to ensure evidence-based management of gynaecological problems, including menopause.</description>
        <link>http://www.biomedcentral.com/1472-6874/9/30</link>
                <dc:creator>Peter Nkwo</dc:creator>
                <dc:source>BMC Women&apos;s Health 2009, 9:30</dc:source>
        <dc:date>2009-10-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-9-30</dc:identifier>
        <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>30</prism:startingPage>
        <prism:publicationDate>2009-10-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
